Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.69 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21760436 | 0.92 | CRBN (0.70) | CRBN | |
| SCHEMBL24601235 | 0.88 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL1413817 | 0.88 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL29488410 | 0.88 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL30569130 | 0.86 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL24637376 | 0.86 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL20234357 | 0.85 | CRBN (0.65) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL29614730 | 0.85 | CRBN (0.65) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL21877059 | 0.84 | CRBN (0.64) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL23267271 | 0.84 | CRBN (0.64) | CRBNIKZF2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025076285-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119019369-A | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240383908-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | HINOVA PHARMACEUTICALS INC. (CN) | 2024-11-21 | — | — | US | disclosed |
| CN-115397821-B | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| EP-4395828-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| CN-115594666-B | Synthesis and application of phosphatase degradation agent | 海创药业股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4368614-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023031801-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |
| CN-115594666-A | Synthesis and application of phosphatase degrading agent | 海创药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023280237-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | 海创药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023280237-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | 海创药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| CN-115397821-A | Bifunctional molecules containing an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-4045496-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | Arvinas Operations, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2020038415-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | CRBN 5/4885IKZF2 25/4885CSNK1A1 1616/4885 |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | CRBN 5/4885IKZF2 25/4885CSNK1A1 1616/4885 |
| US-20240383908-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | DUSP1, PPM1D, PTPN1 | CRBN 576/4885IKZF2 1349/4885CSNK1A1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.